OncoMatch/Clinical Trials/NCT07408089
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
Is NCT07408089 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including BBI-940 and Fulvestrant for breast cancer.
Treatment: BBI-940 · Fulvestrant — This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults with advanced or metastatic breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 wild-type
absence of an ESR1 mutation (Part 2A)
Required: FGFR1 amplification
presence of FGFR1 amplification (Part 2B)
Required: AR overexpression (≥10% by immunohistochemistry)
androgen receptor expression ≥10% by immunohistochemistry
Disease stage
Metastatic disease required
Measurable disease per RECIST v1.1, except for participants enrolled in Part 1A
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapies known to provide clinical benefit, appropriate for disease subtype and study part
Prior treatment with standard therapies known to provide clinical benefit, appropriate for disease subtype and study part, including endocrine therapy with CDK4/6 inhibition for ER+/HER2- disease
Cannot have received: Kinesin inhibitor or degrader
Prior exposure to an inhibitor or degrader of Kinesin
Lab requirements
Blood counts
adequate hematologic function per protocol-defined laboratory criteria
Kidney function
adequate renal function per protocol-defined laboratory criteria
Liver function
adequate hepatic function per protocol-defined laboratory criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEXT Oncology · Austin, Texas
- NEXT Oncology · Houston, Texas
- NEXT Oncology · San Antonio, Texas
- The START Center for Cancer Care · San Antonio, Texas
- NEXT Oncology · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify